BPL’s leadership team has been built up with an emphasis on industry expertise across the life science and pharmaceutical sectors, supported by the team’s broad experience working for leading international companies.
The team believes in energising all employees across every level of the organisation and driving close collaboration between the company’s production, technology and R&D disciplines to deliver long-term strategic growth and support the future success of the business.
Paolo Marcucci was appointed Chairman and CEO of BPL in August 2022.
A lifelong entrepreneur and a corporate leader in the biopharmaceuticals sector, Paolo co-founded Kedrion Biopharma in 2001. He received a degree in Economics, and an MBA at EDHEC Business School. His professional passions have always included business development and strategy.
From 2006, Paolo has been the Chairman and CEO of Kedrion Biopharma, and has been the founder and CEO of several other companies, especially in the pharma and telecommunications sectors.
Paolo has always been committed to putting patients first in everything that Kedrion does, and he will bring to BPL the same spirit in order to meet the needs of patients everywhere who can benefit from plasma-derived therapies. His vision of the new and combined group, which includes both BPL and Kedrion, is to foster future global growth through both organic and acquisitions-led growth, but above all by remaining committed to excellence.
Paolo has been serving on the PPTA (Plasma Protein Therapeutics Association) Global Board of Directors since 2008 and was Chairman of PPTA Global Board from 2013 to 2015. He is married and has two daughters.
Michael Mensa joined BPL in 2015 and was appointed CFO in May 2017 and President and BPL Board member in November 2019. Previously, Michael spent 19 years at GE in various global senior finance roles, mainly in the Energy and Industrials businesses, as well lead roles in M&A and integration processes. His latest role prior to joining BPL was that of CFO for GE’s Software Solutions business. Michael has a dual bachelor’s degree for Finance and Economics from Boston College.
Evan Selig joined BPL in January 2020 after 10 years at VIIV Healthcare, a joint venture of GSK, Pfizer and Shionogi, where he helped the company to develop, launch and grow four new medicines and to implement its legal and compliance framework across functions for its global business. Prior to this, Evan worked at GSK for 4 years supporting the US pharmaceuticals and vaccines businesses with legal matters relating to pricing, contracting, sales and marketing. He spent 6 years as an associate at Reed Smith LLP advising life sciences and health care companies on mergers & acquisitions and strategic commercial and R&D transactions.
Richard Gray joined BPL in 2016, initially as Engineering Director, he was subsequently promoted to Chief Operating Officer in 2019. Richard holds responsibility for all Manufacturing functions, Quality and New Product Development. Richard brings 18 years of experience within Pharmaceuticals and 30 years of experience within manufacturing. He has previously worked for a number of multinational companies including Pfizer, Wyeth, Emerson, Huntsman and ICI. He holds an MBA from Manchester Business School and an Honours Degree in Engineering.
With over 25 years of progressive industry experience Bob has continually demonstrated a passion for building customer focused teams, strong employee engagement and delivering results. Bob has a proven track record of working successfully in commercial leadership roles including commercial operations, sales, marketing and training functions. He deeply understands the evolving healthcare landscape across customer types, business models and therapeutic areas around the globe. Bob joined BPL in 2015, to help build the US organisation and lead the commercial sales team. In his current role, Bob is the US President and Chief Commercial Officer for BPL’s Global Business.